Neurogene (NGNE) CFO executes 9,600-share 10b5-1 stock sale

Rhea-AI Filing Summary

Neurogene Inc. director and President/CFO Christine Mikail Cvijic reported two open‑market sales of common stock totaling 9,600 shares on May 6, 2026. The transactions were executed at weighted average prices of $30.0732 and $32.4358 per share.

According to a footnote, these sales were made under a Rule 10b5‑1 trading plan adopted on August 18, 2025, and the shares sold were held jointly with her spouse, David Cvijic. After the transactions, she directly holds 93,640 shares, including 10,635 restricted stock units vesting on March 13, 2027; 13,533 restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028; and 22,000 restricted stock units vesting annually on February 20, 2027, 2028 and 2029. Of the remaining shares, 9,600 are held jointly with her spouse.

Insider Trade Summary 10b5-1

Net Seller: 9,600 shares ($300,043)

Net Sell 2 txns

Insider Cvijic Christine Mikail

Role President and CFO

Sold 9,600 shs ($300K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,800	$30.0732	$144K
Sale	Common Stock	4,800	$32.4358	$156K

Holdings After Transaction: Common Stock — 98,440 shares (Direct, null)

Footnotes (1)

1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.695, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Total shares sold: 9,600 shares Sale price block 1: $30.0732 per share Sale price block 2: $32.4358 per share +5 more

8 metrics

Total shares sold 9,600 shares Open-market sales of common stock on May 6, 2026

Sale price block 1 $30.0732 per share Weighted average price for 4,800 shares sold

Sale price block 2 $32.4358 per share Weighted average price for 4,800 shares sold

Shares held after sale 93,640 shares Direct holdings following May 6, 2026 transactions

RSUs vesting 2027 (March grant) 10,635 RSUs Granted March 13, 2024; vests March 13, 2027

RSUs vesting 2027–2028 (March grant) 13,533 RSUs Granted March 26, 2025; vests March 26, 2027 and 2028

RSUs vesting 2027–2029 (February grant) 22,000 RSUs Granted February 20, 2026; vests 2027, 2028 and 2029

Jointly held shares 9,600 shares Held jointly by reporting person and spouse

Key Terms

Rule 10b5-1 plan, restricted stock units, weighted average price, open-market sale, +1 more

5 terms

Rule 10b5-1 plan regulatory

"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock units financial

"Includes (a) 10,635 restricted stock units granted on March 13, 2024"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cvijic Christine Mikail

(Last) (First) (Middle)

C/O NEUROGENE INC.

535 W 24TH STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neurogene Inc. [ NGNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/06/2026		S(1)		4,800	D	$30.0732(2)	98,440	D(3)
Common Stock	05/06/2026		S(1)		4,800	D	$32.4358(4)	93,640	D(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.695, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Neurogene (NGNE) report for Christine Mikail Cvijic?

Neurogene reported that director and President/CFO Christine Mikail Cvijic sold a total of 9,600 common shares on May 6, 2026 in two open‑market transactions, according to a Form 4 insider trading report filed with the SEC.

At what prices did the Neurogene (NGNE) CFO sell shares on May 6, 2026?

The Form 4 shows two weighted average sale prices: $30.0732 per share for 4,800 shares and $32.4358 per share for another 4,800 shares. Each block was sold in multiple trades within narrow price ranges.

Was the Neurogene (NGNE) insider sale made under a 10b5-1 trading plan?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5‑1 plan adopted by Christine Mikail Cvijic on August 18, 2025, indicating the sales were pre‑planned rather than discretionary same‑day decisions.

How many Neurogene (NGNE) shares does the CFO hold after the reported sales?

Following the May 6, 2026 transactions, the Form 4 reports that Christine Mikail Cvijic directly holds 93,640 shares of Neurogene common stock, which includes several tranches of unvested restricted stock units scheduled to vest between 2027 and 2029.

What restricted stock units does the Neurogene (NGNE) CFO have outstanding?

The filing notes 10,635 RSUs vesting on March 13, 2027, 13,533 RSUs vesting in equal installments on March 26, 2027 and 2028, and 22,000 RSUs vesting annually on February 20, 2027, 2028 and 2029, all tied to Neurogene stock.

Are any of the Neurogene (NGNE) CFO’s remaining shares held jointly?

Yes. A footnote explains that of the remaining holdings reported after the transactions, 9,600 shares are held jointly by Christine Mikail Cvijic and her spouse, David Cvijic, reflecting shared ownership of part of the position.